6533b85cfe1ef96bd12bc180
RESEARCH PRODUCT
CD1a: a novel biomarker for Barrett's metaplasia?
Giovanni ZummoFrancesca RappaFrancesco CappelloBucchieri Fabiosubject
Oncologymedicine.medical_specialtyBladder cancerbusiness.industrymedicine.medical_treatmentCancermedicine.diseaseCarboplatinGemcitabineRadiation therapyAntigens CD1chemistry.chemical_compoundBarrett EsophagusTransitional cell carcinomaOncologychemistryPaclitaxelTrastuzumabInternal medicinemedicineHumansOncology CD1abusinessBiomarkersmedicine.drugdescription
educational book. Alexandria: American Society for Clinical Oncology, 2001: 226–44. 49 Hussain M, Smith DC, Al-Sukhun S, et al. Preliminary results of HER-2/neu screening and treatment with trastuzumab (Herceptin) (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patients with advanced urothelial cancer. Proc Am Soc Clin Oncol 2002; 21: 800a. 50 Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 2003; 97 (8 suppl): 2064–75. 51 Hussain SA, Ganesan R, Hiller L, et al. Pro-apoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003; 88: 586–92. 52 Stein JP, Ginsberg DA, Grossfield GD, et al . Effect of p21WAF1/CIP1 expression on tumour progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072–79. 53 Hussain SA, Ganesan R, Hiller L, et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 2003; 10: 571–76. 54 Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 2000; 85: 829–35. 55 Hussain SA, James ND. Organ preservation strategies in bladder cancer. Expert Rev Anticancer Ther 2002; 2: 641–51.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-01-01 |